Bright Minds Biosciences Inc. (DRUG)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Ian McDonald | Co-Founder, CEO, President & Director | -- | -- | 1989 |
| Mr. Ryan E. S. K. Cheung B.Com., CA, CPA | Chief Financial Officer | 89.23k | -- | 1978 |
| Dr. Jan Torleif Pedersen M.Sc., Ph.D. | Chief Science Officer & Director | 181.09k | -- | 1965 |
| Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer | 243.54k | -- | 1955 |
| Mr. Alex Vasilkevich | COO & VP of Corporate Development | -- | -- | -- |
| Dr. Emer Leahy M.B.A., Ph.D. | Consultant | -- | -- | 1967 |
Bright Minds Biosciences Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
Description
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available